International Journal of Thyroidology

Table. 4.

Table. 4.

Sources in thyroid cancer studies for medical and non-medical costs of economic evaluation

Type of costs Total N (%) CA+CMAa N (%) CEA+CUAb N (%)
Medical direct costs
Medicare reimbursement 15 (30.6) 5 (10.2) 10 (20.4)
Medicare reimbursement+Raw datac 10 (20.4) 3 (6.1) 7 (14.3)
Raw data 9 (18.4) 4 (8.2) 5 (10.2)
Medicare reimbursement+SRd 8 (16.3) 1 (2.0) 7 (14.3)
SR 4 (8.2) 4 (8.2)
SR+Medicare reimbursement+Raw data 2 (4.1) 2 (4.1)
SR+Raw data 1 (2.0) 1 (2.0)
Total 49 (100.0) 13 (26.5) 36 (73.5)
Non-medical direct costs
Traffic charge 1 (2.0) 1 (2.0)
Not included 48 (98.0) 13 (26.5) 35 (71.4)
Total 49 (100.0) 13 (26.5) 36 (73.5)
Indirect costs
Productivity losse 12 (24.5) 12 (24.5)
Expenses related to death 3 (6.1) 1 (2.0) 2 (4.1)
Productivity loss+Expenses related to death 1 (2.0) 1 (2.0)
Not included 33 (67.3) 12 (24.5) 21 (42.9)
Total 49 (100.0) 13 (26.5) 36 (73.5)

CA: cost analysis, CEA: cost-effectiveness analysis, CMA: cost-minimization analysis, CUA: cost-utility analysis, N: number, SR: systematic review

aCA and CMA studies are presented in a single column, since both evaluation methods compare the costs of the intervention.

bCEA and CUA studies are presented in a single column, since both evaluation methods compare the effectiveness of the intervention.

cClinical trial, registry, or single hospital data.

dSR for medical direct costs.

eLoss of work/revenue/production caused by the unavailability of an employee for any reason.

Int J Thyroidol 2022;15:74-104 https://doi.org/10.11106/ijt.2022.15.2.74
© 2022 Int J Thyroidol